|[March 20, 2013]
Research and Markets: Global Anticoagulants Market to Spike to Over $24 Billion by 2019
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/p9tfcs/new_oral)
has announced the addition of the "New
Oral Anticoagulants Markets" report to their offering.
Anticoagulants can be categorized into five main modalities: low
molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin
inhibitors (DTIs) and factor Xa inhibitors. The U.S. anticoagulants
market, which encompasses over 60% of the global market for
anticoagulants, will grow from $7.06 billion in 2012 to $1.32 billion
in 2019 as it shifts from being monopolized by a single injectable
anticoagulant, warfarin, to once-daily oral anticoagulants.
The "New Oral Anticoagulants Markets" report covers:
- Dabigatran (Pradaxa)
- Rivaroxaban (Xarelto)
- Eliquis (Apixaban)
- Clotting Assays
- Cardiovascular Diseases
- Cardiac Arrhythmia
- Coronary Artery Disease
- Myocardial Infarction
- Heart Valve Replacement
- Deep Vein Thrombosis (DVT)
The "New Oral Anticoagulants Markets" report examines companies
manufacturing anticoagulant equipment and supplies in the world.
Companies covered include: Akers, Anthera, ARYx, AstraZeneca, Boehringer
Ingelheim, Cipla, Daiichi Sankyo, Eisai, Eli Lilly, Genentech,
GlaxoSmithKline, Medicines Company, Medicure, Merck, Novartis,
Ortho-McNeil, Pfizer, Pharmion, Portola and Sanofi.
Detailed charts with sales forecasts and marketshare data are included.
For more information visit http://www.researchandmarkets.com/research/p9tfcs/new_oral
[ Back To Technology News's Homepage ]